Dr. Casey is a pediatric hematologist/oncologist by training and has combined clinical and regulatory experience of 11+ years. Prior to joining DataRevive, Dr. Casey was a clinical reviewer in the oncology office at FDA for over 7 years and an Assistant Professor at University of Rochester Medical Center for 4 years.

Dr. Casey completed her pediatric hematology/oncology training and obtained a Master of Science in Clinical Investigation at Memorial Sloan Kettering Cancer Center/Weill Cornell Medical Center. She subsequently spent four years as an Assistant Professor in the Division of Pediatric Hematology/Oncology at Golisano Children’s Hospital, University of Rochester Medical Center in New York. There she was responsible for clinical care of patients and supervision and education of fellows, residents and medical students, and served as a subinvestigator for Children’s Oncology Group and Dana Farber Cancer Institute clinical trials.

Dr. Casey joined FDA in 2013 where she spent 6+ years as a clinical reviewer on the neuro-oncology, pediatric and rare tumors team in the Office of Oncologic Diseases (former Office of Hematology and Oncology Products) prior to her most recent position as Clinical Team Leader (acting) for the melanoma/sarcoma team. Dr. Casey was the primary clinical reviewer for several marketing applications for new molecular entities, efficacy and safety supplements, as well as numerous Breakthrough Therapy Designation Requests, Fast Track Designation Requests, and Proposed Pediatric Study Requests (PPSRs). She provided consult services to other divisions to advise on topics such as rare tumor drug development, pediatric oncology indications, co-development of devices for oncologic diseases, and radiopharmaceutical development in pediatric and adult oncology indications. She participated in internal and external outreach to further FDA’s mission to facilitate access to safe and effective drugs. She was a member of the Pediatric Oncology Working Group, participated in meetings of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee, and was invited to several conferences and workshops to present on topics including trial design for rare tumor drug development programs, radiopharmaceutical safety, and pediatric legislative initiatives.